ORKA
Oruka Therapeutics, Inc.
$107.96
+2.96%
2026-08-21
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Key Fundamentals
Forward P/E
-40.06
EPS (TTM)
$-2.04
ROE
-18.2%
Profit Margin
0.0%
Debt/Equity
0.23
Price/Book
6.10
Market Cap
$7.35B
Avg Volume (10D)
749K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$115.52
60D Low
$53.62
Avg Volume
1.2M
Latest Close
$107.96
Get breakout alerts for ORKA
Sign up for Breakout Scanner to receive daily notifications when ORKA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Oruka Therapeutics, Inc. (ORKA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ORKA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ORKA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.